The field of oncology immunotherapeutics has exploded recently with the development of immune-checkpoint inhibitors. These drugs enhance antitumor immunity by blocking negative regulators of T-cell function that exist both on immune cells and on tumor cells. There are two classes of immune-checkpoint inhibitors: currently the Food and Drug Administration (FDA) has approved cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibodies 1,2 and programmed cell death-1 (PD-1) antibodies for the treatment of metastatic melanoma. 3, 4 Nivolumab, a PD-1 inhibitor, has also been approved by the FDA for the treatment of metastatic squamous cell lung cancer. 5, 6 These drugs are associated with unique inflammatory side effects known as immune-related adverse events (irAEs). Here, we present recommendations for the management of these events.
Diarrhea/Colitis
Diarrhea is also a common irAE of checkpoint blockade, although it is much more common with the CTLA-4-blocking antibodies compared with those targeting PD-19; the rate of grade 3/4 diarrhea associated with PD-1 blockade is only 1-2 %. 8 and hypothyroidism are the most common endocrinopathies and are typically believed to occur in up to 10 % of patients treated with CTLA-4
blockade. 17, 18 The frequency of endocrinopathy in patients treated with PD-1 or programmed death-ligand 1 agent is less well known, but appears to be less common. 
Conclusion
As immunotherapy emerges as a treatment modality for advanced solid tumors, oncology practitioners will be required to manage inflammatory side effects. Early recognition and aggressive treatment of grade 1-2 irAEs is recommended to prevent patient morbidity and mortality without compromising the efficacy of immune-checkpoint inhibition. Moving forward, it will be imperative to gather prospective data about use of both steroids and steroid-sparing agents to best develop treatment guidelines. ■
